Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

NCT07323056 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

EGFR-mutant Non-small Cell Lung Cancer
Potentially Resectable

Interventions

DRUG: Sacituzumab Tirumotecan and Limertinib

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China